Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jan;41(1):1-3.
doi: 10.1016/j.tips.2019.11.004. Epub 2019 Dec 6.

Targeting Mutant KRAS for Immunogenic Cell Death Induction

Lorenzo Galluzzi  1
Affiliations
Comment

Targeting Mutant KRAS for Immunogenic Cell Death Induction

Lorenzo Galluzzi. Trends Pharmacol Sci. 2020 Jan.

Abstract

Although somatic KRAS mutations are common in human tumors, no inhibitor of mutant KRAS was clinically available until recently. Canon and colleagues describe the ability of a clinically available KRASG12C inhibitor to drive immunogenic cancer cell death, thus constituting a promising combinatorial partner for immune checkpoint blockers.

Keywords: colorectal cancer; lung adenocarcinoma; nivolumab; oxaliplatin; pembrolizumab.

PubMed Disclaimer

Comment on

  • The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
    Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, Lanman BA, Werner J, Rapaport AS, San Miguel T, Ortiz R, Osgood T, Sun JR, Zhu X, McCarter JD, Volak LP, Houk BE, Fakih MG, O'Neil BH, Price TJ, Falchook GS, Desai J, Kuo J, Govindan R, Hong DS, Ouyang W, Henary H, Arvedson T, Cee VJ, Lipford JR. Canon J, et al. Nature. 2019 Nov;575(7781):217-223. doi: 10.1038/s41586-019-1694-1. Epub 2019 Oct 30. Nature. 2019. PMID: 31666701 Clinical Trial.

Publication types

MeSH terms

Substances

LinkOut - more resources